Disposal of non-core products

Disposal of non-core products

London, 22 November 2013 - Sinclair IS Pharma plc (AIM:SPH.L) ("the Group"), the international specialty pharmaceutical company, announces the disposal of non-core products Effederm, Xclair, Salinum and SST for a total cash consideration of £1.1 million.

Effederm, an acne treatment principally sold in France, is being acquired by Labaratoires Bailleul SA. It had revenues of £0.3 million in the year ended 30 June 2013. Hexim Pharmaceuticals Inc have acquired Xclair for radiation dermatitis and xerostomia (dry mouth) treatments SST and Salinum with combined sales of £0.2 million in the year ended 30 June 2013.

These disposals continue the Board's strategy of focusing group resource on a smaller number of key Dermatology brands with clear growth potential in Aesthetics, Wound Care, and Skin Care.

Ends

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner 

Alan Olby

Robert Taylor

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Vijay Barathan

Notes to Editors:

About Sinclair IS Pharma plc - see www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular - Aesthetics, Wound care, and Skin care. The Group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

About Hexim Pharmaceuticals Inc.

Hexim Pharmaceuticals is a leading global Niche and Specialty pharmaceutical company, with Corporate Headquarters in New Jersey and subsidiaries throughout the world including the EU, Asia, the Middle East, Latin America and Eastern Europe. HEXIM is a full-service, vertically integrated company with its own fine chemistry facility, manufacturing plant and in-house R&D and Logistics operations. The company's driving philosophy is to ensure the continuity of essential niche and specialty pharmaceutical drugs that often represent a "last resort therapy" to many patients- but are no longer commercially viable for Big Pharma. Their product pipeline includes over 60 branded prescription and OTC products encompassing a wide variety of therapeutic classes including Oncology, Hematology, Endocrinology, CNS and Emergency Medicine.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.